|
??PK mediated melanoma stem cell oncolysis through non-redundant programmed cell
|
1F31CA154087-01
|
$27,540
|
Colunga, Aric
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
A High-Throughput Model for Human Melanoma
|
5R01CA121118-04
|
$189,600
|
HOLMEN, SHERI
|
NEVADA CANCER INSTITUTE
|
|
A Patient Oriented Research Program for Surgical Oncologists
|
1K24CA138709-01A1
|
$115,705
|
GOYDOS, JAMES
|
UNIV OF MED/DENT NJ-R W JOHNSON MED SCH
|
|
A Phase 0 Trial of Hydroxychloroquine in Patients with Stage III and IV Resectabl
|
1R21CA144019-01A1
|
$320,214
|
Mehnert, Janice
|
UNIV OF MED/DENT NJ-R W JOHNSON MED SCH
|
|
A Phase II Trial of Riluzole in Patients with Advanced Melanoma
|
5R21CA139473-02
|
$343,200
|
GOYDOS, JAMES
|
UNIV OF MED/DENT NJ-R W JOHNSON MED SCH
|
|
A program of immune-based treatments for cancer
|
7K24CA093670-08
|
$182,273
|
CARSON, WILLIAM
|
OHIO STATE UNIVERSITY
|
|
A Proteomics-based Approach to Identifying Mechanisms of Drug Resistance to Targe
|
1F32CA154052-01
|
$47,606
|
Stuart, Scott
|
UNIVERSITY OF COLORADO AT BOULDER
|
|
A Skin Cancer Prevention Video Intervention for Organ Transplant Recipients
|
5R03CA144552-02
|
$74,723
|
LOESCHER, LOIS
|
UNIVERSITY OF ARIZONA
|
|
aAPC-Mediated NKT cell Modulation to Enhance Cancer Immunotherapy
|
5K01CA131487-03
|
$140,940
|
Webb, Tonya
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
ABCB5 P-Glycoprotein in Cancer Multidrug Resistance
|
5R01CA113796-05
|
$291,276
|
Frank, Markus
|
CHILDREN'S HOSPITAL BOSTON
|
|
Abramson Cancer Center of the U of P Core Support Grant
|
3P30CA016520-34S6
|
$7,064,076
|
LERMAN, CARYN
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center of the U of P Core Support Grant
|
3P30CA016520-34S7
|
$100,000
|
LERMAN, CARYN
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center of the U of P Core Support Grant
|
3P30CA016520-34S8
|
$50,000
|
LERMAN, CARYN
|
UNIVERSITY OF PENNSYLVANIA
|
|
Academic Training in Medical Oncology
|
5T32CA009297-27
|
$304,451
|
RIBAS, ANTONI
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Activation of Plasmacytoid Dendritic Cells (pDCs) to Induce Antitumor Activity
|
3P01CA128913-03S1
|
$79,000
|
HWU, PATRICK
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Activation of Plasmacytoid Dendritic Cells (pDCs) to Induce Antitumor Activity
|
5P01CA128913-03
|
$1,837,241
|
HWU, PATRICK
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Adoptive Cell Transfer Immunotherapy of Cancer
|
ZIA BC 010984
|
$1,176,022
|
Rosenberg, Steven
|
CCR (NCI)
|
|
Adoptive T Cell Therapy Following CD25 Lymphodepletion
|
5R21CA137647-02
|
$350,828
|
YEE, CASSIAN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Adoptive T cell Therapy of Melanoma Targeting NY-ESO-1
|
2R01CA104711-06A2
|
$392,915
|
YEE, CASSIAN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Akt3 Signaling as a Therapeutic Target
|
5R01CA127892-03
|
$313,325
|
ROBERTSON, GAVIN
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
|
American College of Radiology Imaging Network
|
5U01CA080098-12
|
$9,041,302
|
Schnall, Mitchell
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
An Anti-tumor Therapy Utilizing EP to Deliver IL-15 into B16.F10 Melanoma
|
5F31CA119950-03
|
$32,853
|
MARRERO, BERNADETTE
|
UNIVERSITY OF SOUTH FLORIDA
|
|
An Appearance-Based Intervention to Reduce Teen Skin Cancer Risk
|
1R01CA134891-01A2
|
$323,341
|
HILLHOUSE, JOEL
|
EAST TENNESSEE STATE UNIVERSITY
|
|
Animal Model and Genotyping Core Support Facility
|
ZIC BC 011047
|
$995,515
|
DuBois, Wendy
|
CCR (NCI)
|
|
Anti-melanoma Activity of Combined Lymphopenia and Immunotherapy
|
4R00CA128825-03
|
$249,000
|
PILON-THOMAS, SHARI
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Anti-stathmin Bifunctional Small Hairpin RNA: Preclinical Dev't of High Potency,
|
N43CO100108-000
|
$199,045
|
Tong, Alex
|
GRADALIS, INC.:1183475
|
|
Antigen specificity, suppressive mechanism & regulation of CD4+ regulatory T cell
|
5R01CA116408-05
|
$258,529
|
Wang, Rongfu
|
BAYLOR COLLEGE OF MEDICINE
|
|
Antigen-specific T-cell Activation, Application to Vaccines for Cancer and AIDS
|
ZIA SC 004020
|
$2,944,136
|
Berzofsky, Jay
|
CCR (NCI)
|
|
Antigenic Determinants on HLA-B7 and -A2
|
5R01CA134060-26
|
$451,153
|
ENGELHARD, VICTOR
|
UNIVERSITY OF VIRGINIA CHARLOTTESVILLE
|
|
Antitumor Mechanisms of anti-CD40/CpG-activated Macrophages
|
5R01CA087025-07
|
$270,001
|
SONDEL, PAUL
|
UNIVERSITY OF WISCONSIN MADISON
|
|
Applying nanosecond pulse electric fields to treat skin cancer
|
5R01CA125722-03
|
$409,354
|
NUCCITELLI, RICHARD
|
BIOELECTROMED CORPORATION
|
|
Aptamer-Based Nanotechnology for Detection of Plasma Melanoma Markers
|
5R21CA137595-02
|
$160,288
|
CLAWSON, GARY
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
|
Arizona Cancer Center-Cancer Center Support Grant
|
3P30CA023074-32S1
|
$100,000
|
Alberts, David
|
UNIVERSITY OF ARIZONA
|
|
Arizona Cancer Center-Cancer Center Support Grant
|
3P30CA023074-32S2
|
$143,893
|
Alberts, David
|
UNIVERSITY OF ARIZONA
|
|
Arizona Cancer Center-Cancer Center Support Grant
|
3P30CA023074-32S3
|
$100,000
|
Alberts, David
|
UNIVERSITY OF ARIZONA
|
|
Arizona Cancer Center-Cancer Center Support Grant
|
5P30CA023074-32
|
$4,161,905
|
Alberts, David
|
UNIVERSITY OF ARIZONA
|
|
Asymmetric Division and Self Renewal of Cancer Stem Cells
|
ZIA BC 011003
|
$198,294
|
Avital, Itzhak
|
CCR (NCI)
|
|
ATF2 in DNA damage response.
|
5R01CA117927-05
|
$376,879
|
RONAI, ZE'EV
|
SANFORD-BURNHAM MEDICAL RESEARCH INSTIT
|
|
Atlanta Regional Community Clinical Oncology Program (ARCCOP)
|
5U10CA045450-24
|
$499,999
|
SEAY, THOMAS
|
ST. JOSEPH'S HOSPITAL
|
|
Augmenting Melanoma Response to B-Raf V600E Targeting
|
1K22CA151638-01
|
$186,840
|
LO, ROGER
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
B-RAF Regulation of the Cell Cycle in Melanoma
|
5R01CA125103-04
|
$256,470
|
APLIN, ANDREW
|
THOMAS JEFFERSON UNIVERSITY
|
|
B7-H1/PD-1 modulation in cancer therapy
|
1R01CA142779-01A1
|
$510,450
|
Chen, Lieping
|
JOHNS HOPKINS UNIVERSITY
|
|
Bay Area Tumor Institute CCOP
|
5U10CA045461-21
|
$461,201
|
Feusner, James
|
BAY AREA TUMOR INSTITUTE
|
|
Baylor College of Medicine Cancer Center
|
2P30CA125123-04
|
$3,089,219
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-03S6
|
$100,000
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-04S1
|
$250,400
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Beaumont Community Clinical Oncology Program
|
2U10CA095860-09
|
$929,588
|
Chmielewski, Gary
|
WILLIAM BEAUMONT HOSPITAL RESEARCH INST
|
|
Beaumont Community Clinical Oncology Program
|
3U10CA095860-09S1
|
$200,000
|
Chmielewski, Gary
|
WILLIAM BEAUMONT HOSPITAL RESEARCH INST
|
|
Bevacizumab plus Ipilimumab in Unresectable Stage III or Stage IV Melanoma
|
1R21CA143832-01A1
|
$332,407
|
HODI, FRANK
|
DANA-FARBER CANCER INSTITUTE
|
|
Bifunctional T cell receptor based immunotherapeutics
|
5R44CA097550-06
|
$990,016
|
WONG, HING
|
ALTOR BIOSCIENCE CORPORATION
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|